Core Viewpoint - Yifan Pharmaceutical announced a comprehensive review of its financial status and asset values, leading to the recognition of asset impairment for the period ending September 30, 2025, with a total impairment provision of 44.31 million yuan for the first nine months of 2025 [2] Financial Assessment - The company conducted a thorough assessment of its consolidated financial statements to identify any signs of asset impairment [2] - The impairment provision of 44.31 million yuan was recorded for the period from January to September 2025 [2]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-064 亿帆医药股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第九 届董事会第二次会议，审议通过了《关于 2025 年前三季度计提资产减值准备的 议案》。现根据《深圳证券交易所股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等规定，将具体情况公告如下： 一、本次计提资产减值准备情况概述 二、本次计提资产减值准备的总体情况 2025 年 1-9 月，公司对存在减值迹象的资产，包括应收款项、存货，计提资 产减值准备 4,431.17 万元，明细如下表： 单位：万元 | 项目 | 资产名称 | 年 月计提 2025 1-9 资产减值准备金额 | | 占 年度 2024 经审计净利润的比例 | | | --- | --- | --- | --- | --- | --- | | | 应收款项—应收账款及 票据 应收款项—其他应 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-062 亿帆医药股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第九届董事会第二次会议于 2025 年 10 月 20 日以邮件的方式发出通知，于 2025 年 10 月 30 日以现场加通讯 表决的方式在公司一楼会议室召开，其中以通讯表决方式参加会议的董事为林行 先生、曾玉红女士、刘梅娟女士。会议应出席董事 6 名，实际出席董事 6 名，会 议由董事长程先锋先生主持，公司高级管理人员列席会议。本次会议的召集和召 开符合《公司法》和《公司章程》等有关规定。 （一）会议以6票同意、0票反对、0票弃权的结果，审议通过了《公司2025 年第三季度报告》 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2025 年第三季度报告》。 （二）会议以6票同意、0票反对、0票弃权的结果，审议通过了《关于2025 年前三季度计提资产减值准备的议案》 具体内容详见 ...

Core Insights - Yifan Pharmaceutical reported a third-quarter revenue of 1.288 billion yuan, representing a year-on-year growth of 5.01% [1] - The net profit attributable to shareholders for the third quarter was 84.14 million yuan, a decrease of 25.64% year-on-year [1] - For the first three quarters, the company achieved a total revenue of 3.923 billion yuan, reflecting a year-on-year increase of 1.67% [1] - The net profit attributable to shareholders for the first three quarters was 388 million yuan, showing a year-on-year growth of 5.84% [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥1,287,599,282.86, representing a 5.01% increase year-over-year[5] - Net profit attributable to shareholders decreased by 25.64% to ¥84,135,651.43 compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses increased by 7.76% to ¥78,189,267.95[5] - The company reported a basic earnings per share of ¥0.07, down 22.22% from the previous year[5] - Total operating revenue for the period reached ¥3,922,709,366.04, an increase from ¥3,858,211,534.78 in the previous period, reflecting a growth of approximately 1.67%[26] - The company's net profit margin improved, with net profit attributable to shareholders increasing to ¥4,734,556,936.75 from ¥4,468,409,241.36, representing a growth of approximately 5.96%[25] - The net profit for the current period is CNY 360,252,018.99, an increase from CNY 307,759,997.51 in the previous period, representing a growth of approximately 17%[27] - The total profit for the current period is CNY 434,810,968.73, compared to CNY 385,056,800.16 in the previous period, indicating an increase of about 13%[27] - The operating profit for the current period is CNY 435,706,848.84, up from CNY 383,633,544.49, reflecting a growth of around 14%[27] - The total comprehensive income for the current period is CNY 400,987,032.02, compared to CNY 296,934,756.14 in the previous period, marking an increase of approximately 35%[27] - The basic and diluted earnings per share for the current period are both CNY 0.32, up from CNY 0.30 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,106,158,077.09, a 6.68% increase from the end of the previous year[5] - Current assets totaled ¥4,313,556,790.11, up from ¥3,778,271,166.02, marking an increase of about 14.16%[23] - Non-current assets increased to ¥8,792,601,286.98 from ¥8,507,516,922.73, reflecting a growth of approximately 3.35%[24] - Total liabilities rose to ¥4,397,743,703.79 from ¥3,858,992,750.77, indicating an increase of about 13.96%[25] - The company's cash and cash equivalents decreased slightly to ¥875,507,636.63 from ¥889,388,507.75, a decline of approximately 1.0%[23] - The cash and cash equivalents at the end of the period amount to CNY 811,104,642.08, compared to CNY 899,762,155.39 at the end of the previous period[31] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥326,150,987.29, a decrease of 7.71%[5] - The cash flow from operating activities for the current period is CNY 326,150,987.29, a decrease from CNY 353,409,624.07 in the previous period[30] - The cash flow from investing activities shows a net outflow of CNY 344,369,481.85, compared to a net outflow of CNY 368,697,671.99 in the previous period[30] - The cash flow from financing activities has a net inflow of CNY 53,987,074.19, down from CNY 344,642,647.40 in the previous period[31] - The company received CNY 3,864,821,449.72 in cash from sales of goods and services, slightly up from CNY 3,840,344,662.08 in the previous period[29] Investments and Projects - The company experienced a 52.73% increase in construction in progress, totaling ¥1,232,730,128.75, due to investments in new projects[10] - Financial expenses decreased by 31.04% to ¥34,375,911.44, attributed to increased exchange gains and reduced interest expenses[12] - The company reported a significant decrease in investment income, with a loss of ¥22,725,516.58, compared to a loss of ¥6,930,848.09 in the previous year[12] - The company plans to continue focusing on the development of innovative and self-researched drugs to drive revenue growth[5] - The company is actively expanding its product pipeline with multiple drug registrations and approvals in progress[17][18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,624[14] - The largest shareholder, Cheng Xianfeng, holds 40.82% of shares, totaling 496,526,307 shares, with 372,394,730 shares pledged[14] - The 2022 employee stock ownership plan holds 6.7754 million shares, representing 0.56% of the total share capital[20] - The company has not identified any related party relationships among shareholders other than those disclosed[15] Regulatory and Clinical Developments - The subsidiary Suzhou Yifan Pharmaceutical Co., Ltd. received a registration notice for the oral drug Benzylbutyric Acid Glycerol Ester on July 16, 2025[17] - The company completed the Ib phase clinical trial for the drug Duanjin Detoxification Capsule, targeting opioid addiction, achieving expected results[17] - The company received a registration approval for Oxytocin Injection in Tajikistan on August 26, 2025[18] Management and Strategy - The company has appointed new senior management and completed the board restructuring, which may impact future strategic directions[22] - The company signed a maximum guarantee contract with multiple banks to support its subsidiaries' financing needs[16]

Core Insights - The company has been implementing a long-term strategy of "integration, innovation, and internationalization" since 2014, focusing on enhancing its core competitive advantages through increased R&D investment [2] - As of the 2025 semi-annual report, the company achieved a revenue of 2.635 billion yuan, with approximately 2.254 billion yuan, or 85.53%, coming from pharmaceutical-related revenues [2] Company Strategy - The company emphasizes maintaining its existing business while continuously innovating and upgrading its operations [2] - The primary industry development direction remains focused on pharmaceutical formulations and active pharmaceutical ingredients [2]

证券日报网讯亿帆医药10月30日在互动平台回答投资者提问时表示，公司与美国合作方的销售提成收 入，其权利义务在第三季度已经形成。公司在获取第三季度销售数据后，将其确认为第三季度的收入。 （文章来源：证券日报） ...

Core Viewpoint - Company’s wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has participated in the 11th national centralized drug procurement organized by the National Joint Procurement Office, with some products expected to be selected for this procurement [1][2]. Group 1: Product Information - The products proposed for selection include Ephedrine Hydrochloride Injection and Meprobamate Injection, which received drug registration certificates from the National Medical Products Administration in March 2023 and August 2024, respectively [2]. - The final prices and supply provinces for the selected products will be based on the data released by the Joint Procurement Office [1]. Group 2: Impact on the Company - The sales revenue from the proposed selected products currently accounts for a small proportion of the company's total revenue, and it is expected that there will be no significant impact on the company's performance in the short term [2]. - If the company successfully signs procurement contracts and implements them, it will enhance the accessibility of the products and improve the company's brand influence [2].

Group 1 - Core viewpoint: Yifan Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected, including adrenaline hydrochloride injection [1] - Revenue composition for the first half of 2025: Pharmaceuticals accounted for 85.53%, pharmaceutical raw materials and intermediates 11.47%, and high molecular materials 3.0% [1] - Current market capitalization of Yifan Pharmaceutical is 16 billion yuan [1]

Core Viewpoint - Yifan Pharmaceutical (002019) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected for this procurement [1] Group 1 - Yifan Pharmaceutical's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., is involved in the bidding process for the centralized procurement [1] - The products involved in the bidding include Adrenaline Hydrochloride Injection and Meprobamate Injection, which are intended to be selected in this round of procurement [1]